Business
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
MOUNTAIN VIEW, Calif., April 16, 2025--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that it is increasing production of its FDA-cleared RenovoCath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists.
About this update from Renovorx, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c1e19947c8e3111da1f0431a059e192e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TtdECwZi_YwwWWEZwRsJug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c1e19947c8e3111da1f0431a059e192e","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/IOwNHrjnIkjLVOSR28wdQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/c1e19947c8e3111da1f0431a059e192e","width":1024,"height":512}},"lazy":false},{"type":"text","content":"RenovoCath is proudly made in America at a facility in North Barrington, IL","length":75,"tagName":"p","attribs":{}},{"type":"text","content":"RenovoRx management and board members purchased over 140,000 shares of RenovoRx stock during recent open trading window, signaling their confidence in RenovoRx’s future","length":168,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., April 16, 2025--(BUSINESS WIRE)--RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that it is increasing production of its FDA-cleared RenovoCath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists. The principal manufacturer of RenovoCath devices is Medical Murray Inc., based in the U.S. in North Barrington, IL.","length":652,"tagName":"p"},{"type":"text","content":""As we anticipated, we are seeing growing demand for our proprietary RenovoCath device. We expect first-quarter 2025 revenue from RenovoCath to reach the low six-figure range, with continued sequential growth quarter-over-quarter throughout the remainder of the year," said Shaun Bagai, Chief Executive Officer of RenovoRx. "We estimate that our initial total addressable market for RenovoCath is approximately $400 million in peak annual U.S. sales. We further believe we can capture this market over time with a very smal...